HMPL-523(300mg PO QD) + Placebo
Phase 2/3Active 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Warm Antibody Autoimmune Hemolytic Anemia
Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Trial Timeline
Sep 30, 2022 → Nov 1, 2026
NCT ID
NCT05535933About HMPL-523(300mg PO QD) + Placebo
HMPL-523(300mg PO QD) + Placebo is a phase 2/3 stage product being developed by HUTCHMED for Warm Antibody Autoimmune Hemolytic Anemia. The current trial status is active. This product is registered under clinical trial identifier NCT05535933. Target conditions include Warm Antibody Autoimmune Hemolytic Anemia.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05535933 | Phase 2/3 | Active |
Competing Products
12 competing products in Warm Antibody Autoimmune Hemolytic Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ianalumab + Placebo | Novartis | Phase 3 | 77 |
| rituximab (Mabthera®) + Placebo | Roche | Phase 3 | 77 |
| rilzabrutinib | Sanofi | Phase 2 | 51 |
| Isatuximab SAR650984 | Sanofi | Phase 2 | 51 |
| parsaclisinib + placebo | Incyte | Phase 3 | 74 |
| RVT-1401 680 mg/weekly + RVT-1401 340 mg/weekly | Immunovant | Phase 2 | 49 |
| APL-2 | Apellis Pharmaceuticals | Phase 2 | 47 |
| Obexelimab + Obexelimab | Zenas BioPharma | Phase 3 | 72 |
| ANX005 | Annexon | Phase 2 | 47 |
| Fostamatinib 150 mg bid | Rigel Pharmaceuticals | Phase 2 | 44 |
| Fostamatinib disodium | Rigel Pharmaceuticals | Phase 3 | 69 |
| Fostamatinib disodium + Placebo | Rigel Pharmaceuticals | Phase 3 | 69 |